Key Points Rescheduling could expand Tilray’s U.S. medical cannabis opportunity. U.S. cannabis operators could benefit more immediately from rescheduling. Tilray looks stronger, but federal reform remains uncertain. 10 stocks we like better than Tilray Brands › President Donald Trump directed federal officials to move quickly on marijuana rescheduling, and that effort just survived another legal challenge. Last week, a federal appeals court rejected a request from marijuana opponents to temporarily block the administration from moving forward with broader rescheduling while their lawsuits are considered.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.